Search - tctmd.com

Displaying 721 - 740 of 1032

Sort: Relevancy | Date

Presentation TCT 2015

BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold - Six-Month Clinical, Angiographic and Imaging Outcomes

Presenter: Ioanna Kosmidou, Michael Haude

October 12, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

Presenter: Ioanna Kosmidou, Bernard R. Chevalier

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold Six-Month Clinical, Angiographic, and Imaging Outcomes

Presenter: Dean J. Kereiakes, Ron Waksman, Davide Capodanno, Michael Haude

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

A Tribute to Liliana Grinfeld

Presenter: Dimitrios Alexopoulos, Roxana Mehran

October 12, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Bernard Chevalier

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

News Conference News TCT 2015

Absorb BVS Matches Xience V in Chinese Patients

Todd Neale

October 12, 2015

Presentation TCT 2015

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? NO!

Presenter: Carlo Di Mario, Eberhard Grube, Daniel I. Simon

October 11, 2015

Presentation TCT 2015

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? YES!

Presenter: Carlo Di Mario, Eberhard Grube, Manel Sabate

October 11, 2015

Presentation TCT 2015

Case 2: A Case Where Metallic DES Was Preferred Over BVS

Presenter: Carlo Di Mario, Eberhard Grube, Nicolas M. Van Mieghem

October 11, 2015

Advertisement

BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold - Six-Month Clinical, Angiographic and Imaging Outcomes

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold Six-Month Clinical, Angiographic, and Imaging Outcomes

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

A Tribute to Liliana Grinfeld

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Absorb BVS Matches Xience V in Chinese Patients

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? NO!

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? YES!

Case 2: A Case Where Metallic DES Was Preferred Over BVS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content